DANIEL LE: Open Payments
NPI 1295244325 · GARDEN GROVE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,174 in 35 payments from 10 companies in 2025. Trend: 2023 $1,493 · 2024 $2,481 · 2025 $1,174
Food & beverage: $774Speaker / faculty: $400
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation | 4 | $509 |
| Lilly USA, LLC | 9 | $169 |
| Novo Nordisk Inc | 7 | $158 |
| Abbott Laboratories | 6 | $145 |
| GlaxoSmithKline, LLC. | 2 | $56 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $43 |
| Amphastar Pharmaceuticals, Inc. | 2 | $39 |
| Dexcom, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Mannkind Corporation | 1 | $16 |
Products named: Omnipod, MOUNJARO, FREESTYLE LIBRE 3, Wegovy, Ozempic, NUCALA, JARDIANCE, Dexcom G6 Transmitter.
Industry payments across CA — which companies pay providers there.
